IVSX - ETF AI Analysis
Top Page
Applied Finance IVS International SMID ETF (IVSX)
IVSX, the Applied Finance IVS International SMID ETF, has a solid overall rating driven mainly by strong performers like ONO Pharmaceutical, PERSOL Holdings, and Temenos, which combine healthy financials with supportive price trends and reasonable or attractive valuations. However, several holdings such as Leopalace21 and IOS face bearish technical momentum, high leverage, or slowing revenue, which weigh on the fund’s appeal. The main risk factor is the presence of multiple holdings with bearish technical signals and valuation concerns, which could increase short-term volatility even though the overall portfolio quality is still respectable.
IVSX vs. SPDR S&P 500 ETF (SPY)
- AUM
- 4.88M
- Region
- Developed Markets
- Expense Ratio
- 0.75%
- Beta
- 0.89
- Issuer
- Applied Finance
- Inception Date
- Feb 19, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
IVSX Summary
Applied Finance IVS International SMID ETF (IVSX) is an actively managed fund that focuses on small- and mid-sized companies in developed countries outside the U.S., rather than tracking a fixed index. It spreads investments across many sectors and regions such as Japan, the UK, and Europe, with holdings like Relo Group and Swissquote Group. Someone might invest in IVSX to seek long-term growth and add international diversification beyond large, well-known global companies. A key risk is that smaller international stocks can be more volatile and can go up and down more sharply than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, with a team doing in-depth research to pick international small- and mid-cap stocks rather than just tracking an index.
What would affect this ETF?
This ETF could benefit if developed markets outside North America grow steadily, interest rates stabilize or fall, and international small- and mid-sized companies in areas like industrials, consumer cyclical, and technology continue to expand, helping holdings such as Swissquote, Temenos, and IONOS. On the other hand, it could be hurt by global slowdowns, higher interest rates that pressure smaller companies and financial or real estate names, currency swings, or new regulations affecting key countries and sectors like airlines, utilities, and financial services.
IVSX Top 10 Holdings
IVSX leans into developed markets outside North America, with a clear tilt toward Japanese and European small and mid-caps. Rising names like France’s Edenred and Japan’s ONO Pharmaceutical are doing much of the heavy lifting, while Leopalace21 has cooled recently after a strong run. On the flip side, Swissquote and St. James’s Place are dragging the fund, with their shares stuck in reverse despite solid underlying businesses. Overall, the ETF is broadly diversified across sectors, but financial and service-oriented names are setting the tone for performance.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 JP:8848 | Leopalace21 | 1.89% | $92.25K | JPY 314.20B | 58.49% | 58Neutral |
 JP:4528 | ONO Pharmaceutical Co | 1.48% | $72.44K | JPY 1.06T | 20.19% | 75Outperform |
 FR:EDEN | EDENRED | 1.61% | $78.65K | EUR 5.69B | -7.32% | 62Neutral |
 JP:8876 | Relo Group | 1.60% | $77.94K | JPY 373.66B | 47.32% | 68Neutral |
 CH:SQN | Swissquote Group Holding Ltd. | 1.57% | $76.83K | CHF 5.24B | -32.68% | 62Neutral |
 IT:LTMC | Lottomatica Group S.P.A. | 1.43% | $69.81K | EUR 6.01B | 22.61% | 63Neutral |
 JP:2181 | PERSOL HOLDINGS CO | 1.09% | $53.40K | JPY 661.69B | 13.57% | 76Outperform |
 CH:TEMN | Temenos | 1.09% | $53.05K | CHF 5.26B | 3.22% | 78Outperform |
 GB:STJ | St. James's Place | 1.03% | $50.55K | GBP 5.14B | -21.24% | 64Neutral |
 DE:EVD | CTS Eventim AG & Co. KGaA | 1.07% | $52.28K | EUR 6.23B | -17.06% | 69Neutral |
IVSX Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IVSX, the sentiment is Neutral. The current price of 25.66 is above the 20-day moving average (MA) of 25.66, below the 50-day MA of 25.79, and compared to the 200-day MA of , indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 48.62 is Neutral, neither overbought nor oversold. The STOCH value of 38.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IVSX.
IVSX Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IVSX | $25.66 | $27.00(5.21% Upside) | $4.88M | 0.75% | 61Neutral |
 QUIZ | $28.04 | $33.98(21.17% Upside) | $96.92M | 0.55% | 65Neutral |
 JIDE | $50.60 | $60.22(19.02% Upside) | $28.57M | 0.55% | 68Neutral |
 TACN | $28.27 | $33.90(19.91% Upside) | $24.17M | 0.00% | 66Neutral |
 ENHI | $26.48 | $32.74(23.68% Upside) | $21.39M | 0.27% | 66Neutral |
 IVSI | $29.22 | $34.26(17.27% Upside) | $9.48M | 0.65% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IVSX | Applied Finance IVS International SMID ETF | 25.66 | 0.38 | 1.50% | |
| QUIZ | Zacks Quality International ETF | 28.04 | 2.40 | 9.35% | |
| JIDE | JPMorgan International Dynamic ETF | 50.60 | 1.28 | 2.60% | |
| TACN | T. Rowe Price Active Core International Equity ETF | 28.27 | 3.04 | 12.04% | |
| ENHI | iShares Enhanced International Active ETF | 26.48 | 2.23 | 9.22% | |
| IVSI | Applied Finance IVS International Large ETF | 29.21 | 3.64 | 14.25% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.